Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Experimental drug based on natural enzyme 'can kill MRSA'

  • 1 Comment

Scientists believe they have found an alternative to antibiotics which could be used to combat superbugs such as MRSA.

A small test study suggested the new drug, an enzyme that solely targets the bacteria in MRSA, was effective against the infection with scientists claiming the likelihood of the bug becoming resistant was “very limited”.

Dutch biotech firm Micreos presented the findings at the EuroSciCon meeting, called Antibiotics Alternatives for the New Millenium, in London on 5 November.

“With the increasing prevalence of multi-drug-resistant bacteria, new strategies for the treatment of bacterial infections are needed”

Bjorn Herpers

Micreos chief executive Mark Offerhaus hailed it as a “new era in the fight against antibiotic resistant bacteria” and said “millions of people stand to benefit”.

MRSA, or methicillin-resistant Staphylococcus aureus, is resistant to many antibiotics and poses a serious hazard in hospitals and nursing homes – though concerted action in NHS acute settings has reduced its incidence in recent years.

Politicians and scientists have warned of the need to find a cure for infections that have become resistant, with David Cameron this year stating it was a “very real and worrying threat” that could send medicine “back into the dark ages”.

The new drug, marketed as Staphefekt, is based on naturally occurring enzymes called endolysins, which are found in viruses and kill bacteria in a different way to antibiotics.

In one observational study, Staphefekt killed MRSA in five out of six people suffering skin conditions such as dermatitis and eczema.


Bjorn Herpers

Clinical biologist Dr Bjorn Herpers told the conference: “The results are exciting, and demonstrate the potential this technology has to revolutionise the way we treat certain bacterial infections.

“With the increasing prevalence of multi-drug-resistant bacteria, new strategies for the treatment of bacterial infections are needed,” he said.

“As well as being less prone to resistance induction than antibiotics, endolysins (enzymes) destroy only their target bacterial species, leaving the beneficial bacteria alone,” he added.

The firm is to conduct clinical trials of Staphefekt and is looking to expand them internationally.

  • 1 Comment

Readers' comments (1)

  • Wow, what brilliant news if the trials are are successful. A revolution in the fight against bacteria and the overuse of antibiotics. Well done to this team.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs